SKIN

NanoPass Sharing Microneedle Device with Pharma Partners for COVID-19 Vaccine

NanoPass is sharing its proprietary MicronJet microneedle device with vaccine and immunotherapy companies to help in the efforts to develop a safe, effective and affordable vaccine against SARS-COV-2, novel coronavirus.

WEARABLE INJECTORS: CHOOSING & TESTING OPTIMAL ADHESIVES

Neal Carty and Deepak Prakash highlight the importance of choosing and testing adhesives for optimal wearable drug delivery device performance.

“PRESERVATIVE FREE” – THE SKIN MICROBIOME’S CLOSE FRIEND

Dr Marie-Christine Klein

“PRESERVATIVE FREE” – THE SKIN MICROBIOME’S CLOSE FRIEND

Marie-Christine Klein, Andreas Bilstein and Julia Krüger discuss the effects of preservatives on the skin microbiome and consider new technologies that minimise the percentage of preserving agents used in cosmetic formulations.

DE-RISKING COMBINATION PRODUCT REGISTRATION FOR SEMI-SOLIDS WITH APTAR PHARMA’S AIRLESS<sup>+</sup> SYSTEM – AN INTERVIEW WITH STEFAN HELLBARDT

Dr Stefan Hellbardt

DE-RISKING COMBINATION PRODUCT REGISTRATION FOR SEMI-SOLIDS WITH APTAR PHARMA’S AIRLESS⁺ SYSTEM – AN INTERVIEW WITH STEFAN HELLBARDT

Stefan Hellbardt discusses the increasing demand for airless systems in the dermal drug delivery market, the advantages of these systems and Aptar Pharma’s own offering in this space, including its Airless+ packaging system and Extended Support services.

UNLOCKING THE POTENTIAL OF MICRONEEDLE TECHNOLOGY

Bart van Oorschot

UNLOCKING THE POTENTIAL OF MICRONEEDLE TECHNOLOGY

Bart van Oorschot and Maarten Smit discuss the exciting potential of microneedle-based delivery systems to transform the drug delivery industry, the challenges faced by this technology and how the use of an applicator may be the way to overcome them.

SAY “NO MORE” TO NEEDLES: NEEDLE-FREE SELF-INJECTION TECHNOLOGY FOR PAINLESS, BETTER CARE

SAY “NO MORE” TO NEEDLES: NEEDLE-FREE SELF-INJECTION TECHNOLOGY FOR PAINLESS, BETTER CARE

Alina Su discusses the need for improved and optimised remote healthcare to meet current challenges in the industry, and introduces Telosis, the company’s patent-pending connected needle-free injection device that is poised to provide answers to these challenges.

THE NEXT GENERATION OF MICRONEEDLES: HARNESSING A BILLION YEARS OF EVOLUTION

Dr Gabriel Villar

THE NEXT GENERATION OF MICRONEEDLES: HARNESSING A BILLION YEARS OF EVOLUTION

Gabriel Villar and Ethan Miller consider examples of nature’s solutions to four challenges faced by microneedles for drug delivery. For each challenge, the authors explain how a natural organism has tackled it and what lessons may be directly applied to microneedle design.

AN AIRLESS SPRAY NOZZLE TO PRODUCE A FINE AND SOFT MIST

Dr Claire Authesserre

AN AIRLESS SPRAY NOZZLE TO PRODUCE A FINE AND SOFT MIST

Claire Authesserre and Florian Corne discuss the current challenges faced by the topical spray-based delivery of therapeutics and how EVEON’s Ad-Mist™ spray nozzle overcomes these challenges to harness the potential of this delivery route.

3D-PRINTED HOLLOW MICRONEEDLES: A NEW FRONTIER FOR TRANSDERMAL DRUG DELIVERY

Dr Dimitrios Lamprou

Queen's University Belfast

3D-PRINTED HOLLOW MICRONEEDLES: A NEW FRONTIER FOR TRANSDERMAL DRUG DELIVERY

Dimitrios Lamprou and Essyrose Mathew discuss the potential of 3D-printed hollow microneedles for transdermal drug delivery.

Excipient Choices and Why They Matter in Topical Formulations

Bora Pharmaceutical CDMO

Excipient Choices and Why They Matter in Topical Formulations

Daryl Bassett and David Barnes show how the choice of common excipients can have a material impact on manufacturing success, quality and, ultimately, commercial success for topical formulations, which generally require the incorporation of more excipients than other products to deliver their API payload effectively.

SUCCESSFULLY BALANCING THE NEEDS OF THE PLANET WITH THE NEEDS OF THE PATIENT

SUCCESSFULLY BALANCING THE NEEDS OF THE PLANET WITH THE NEEDS OF THE PATIENT

Christophe Marie, Taylor Price and Julien Storz chart the commitments and progress made to date by Aptar in achieving its sustainability targets. The authors also provide examples of integrated, circular economy initiatives undertaken by Aptar Pharma at a product solution level and comment on concrete commitments that can be made to further progress towards sustainability.

EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY

EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY

Charlie Dean, Kay Sinclair and Brennan Miles provide an overview of eight terms key to a common understanding in the ongoing, and crucial, discussion surrounding sustainability.

THE FOURTH INDUSTRIAL REVOLUTION – ROBOTICS AND THE LABORATORY

INDUSTRIALISATION

Prof Marc Brown

THE FOURTH INDUSTRIAL REVOLUTION – ROBOTICS AND THE LABORATORY

Marc Brown and Jon Lenn look at MedPharm’s implementation of automated robotic systems in enhancing workflow and the company’s plans for the future implementation of robotics in formulation development.

SERITECH LEVERAGES FAST-DETACHING, DISSOLVING MICRONEEDLE FOR TRANSDERMAL DRUG DELIVERY

Mr Richard Joye

SERITECH LEVERAGES FAST-DETACHING, DISSOLVING MICRONEEDLE FOR TRANSDERMAL DRUG DELIVERY

Richard Joye and Tim Morch discuss the advantages of using dissolvable microneedles for the delivery of vaccines, particularly in regards to storage and transport, and introduce SeriTech’s fast-detaching dissolvable microneedle technology.

WHY THE CONSISTENT CHALLENGES SURROUNDING MAPS ARE DISSOLVING FAST

Dr Sebastian Braun

WHY THE CONSISTENT CHALLENGES SURROUNDING MAPS ARE DISSOLVING FAST

Sebastian Braun discusses the current state of microneedle-based transdermal drug delivery, covering available microneedle delivery methods, the US FDA’s current stance on microneedle technologies and LTS’s microarray patch (MAP) system and the possibilities it represents.

MICRONEEDLES FOR INTRADERMAL DELIVERY OF CANCER VACCINES

Dr John Vasilakos

Kindeva Drug Delivery

MICRONEEDLES FOR INTRADERMAL DELIVERY OF CANCER VACCINES

John Vasilakos discusses the immuno-oncology market. He examines the role of cancer vaccines in supplementing other immuno-oncology therapies, as well as the value of delivering cancer vaccines intradermally.

AIRLESS DRUG DELIVERY: WIDELY ACCEPTED, ACCESSIBLE AND AVAILABLE

Dr Stefan Hellbardt

AIRLESS DRUG DELIVERY: WIDELY ACCEPTED, ACCESSIBLE AND AVAILABLE

Stefan Hellbardt reflects on the role of Airless technology in the dermal drug delivery market and the benefits it offers.

ENSURING FORMULATION PROTECTION AND PATIENT CARE WITH AIRLESS DISPENSERS

ENSURING FORMULATION PROTECTION AND PATIENT CARE WITH AIRLESS DISPENSERS

Audrey Chandra, Manuela Basso and Raphaële Audibert consider Nemera’s holistic approach to dermal drug delivery, explaining why airless technology is important for dermal pharmaceutical applications

AN ANGLED MICRONEEDLE PATCH FOR ENHANCED DRUG AND VACCINE DELIVERY

Dr Nicky Bertollo

AN ANGLED MICRONEEDLE PATCH FOR ENHANCED DRUG AND VACCINE DELIVERY

Nicky Bertollo, Ronan Byrne and Andrew Muddle introduce Pharma Latch – a user-centric angled microneedle patch technology. They discuss its key benefits, such as dramatically increased payload potential, precision, low cost and variable patch-wear times, and highlight how Pharma Latch has the potential to overcome many of the limitations of existing routes of administration for therapeutics and vaccines.

PRODUCT SHOWCASE: Logan Instruments’ Transdermal Testing Portfolio

Logan Instruments

PRODUCT SHOWCASE: Logan Instruments’ Transdermal Testing Portfolio

Logan Instruments, a provider of laboratory instrumentation to the global pharmaceutical and cosmetics industries, with a focus on physical, dissolution and transdermal testing systems, showcases its pioneering transdermal testing system offering.

MEDICSEN: NEEDLE-FREE SMARTPATCH FOR PAINLESS DRUG DELIVERY

Dr Eduardo Jorgensen

MEDICSEN: NEEDLE-FREE SMARTPATCH FOR PAINLESS DRUG DELIVERY

Eduardo W Jørgensen, Juan César de Mercado and José Carlos Montesinos describe the Smartpatch, a novel technology for subcutaneous delivery of drugs via a comfortable, pain-free patch using sonophoresis, based on Medicsen’s patented miniaturised ultrasound technology.

INNOVATION AND AUTOMATION IN TOPICAL FORMULATION DEVELOPMENT

INDUSTRIALISATION

Prof Marc Brown

INNOVATION AND AUTOMATION IN TOPICAL FORMULATION DEVELOPMENT

Marc Brown, Jon Lenn and Charles Evans discuss the challenges faced by the pharmaceutical industry during the development of topical delivery formulations, and how MedPharm’s performance testing models help identify and mitigate risks during the process.

INTERVIEW WITH AARON MANN, CHIEF EXECUTIVE OFFICER, KINDEVA

INTERVIEW WITH AARON MANN, CHIEF EXECUTIVE OFFICER, KINDEVA

In this exclusive interview with ONdrugDelivery, Aaron Mann discusses how Kindeva is positioned to move forward as a major CDMO specialising in inhalation and transdermal dosage forms, having been formed from 3M’s drug delivery in May 2020. We also cover the impact of Covid-19, environmental sustainability, and current challenges faced by the pharmaceutical industry.

ROUNDTABLE: JEREMY DRUMMOND, MEDPHARM; STEPHEN RODE, LONZA; AND TORKEL GREN, RECIPHARM

Dr Jeremy Drummond

ROUNDTABLE: JEREMY DRUMMOND, MEDPHARM; STEPHEN RODE, LONZA; AND TORKEL GREN, RECIPHARM

In this roundtable discussion, Jeremy Drummond, Stephen Rode and Torkel Gren discuss trends with different drug dosage forms for different routes of administration, the rise of patient centricity including the shift from the blockbuster model to more tailored products.

VAXESS RECEIVES BARDA CONTRACT FOR COVID-19 + SEASONAL FLU VACCINE IN ITS SMART-RELEASE MICRONEEDLE PATCH

VAXESS RECEIVES BARDA CONTRACT FOR COVID-19 + SEASONAL FLU VACCINE IN ITS SMART-RELEASE MICRONEEDLE PATCH

Vaxess Technologies is to receive US BARDA funding to demonstrate the feasibility of its MIMIX microneedle patch technology for a COVID-19 vaccine, with the aim of designing and developing a “combination seasonal protection patch”, incorporating COVID-19 + seasonal influenza protection.

INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES

INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES

Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.

AN INJECTION OF CONNECTED NEEDLE-FREE INNOVATION

Portal Instruments

AN INJECTION OF CONNECTED NEEDLE-FREE INNOVATION

Barb Taylor discusses the next generation of needle-free injection devices, which incorporate connectivity.

SKIN-MOUNTABLE FLEXIBLE NEEDLE PATCH FOR MINIMALLY INVASIVE CONTROLLED DRUG DELIVERY

Dr Chi Hwan Lee

Weldon School of Biomedical Engineering

SKIN-MOUNTABLE FLEXIBLE NEEDLE PATCH FOR MINIMALLY INVASIVE CONTROLLED DRUG DELIVERY

Chi Hwan Lee and Eun Kwang Lee introduce a skin-mountable flexible needle patch and discuss its applications in non-invasive drug delivery applications.

SYNERGISING EXCIPIENTS TO BOOST SKIN DELIVERY

SYNERGISING EXCIPIENTS TO BOOST SKIN DELIVERY

Cécile Morin and Delphine Marchaud discuss combining polar and apolar excipients in topical formulations in order produce synergies that maximise the performance of the drug.

DISSOLVABLE MICRONEEDLES: APPLICATIONS AND OPPORTUNITIES

Dr Jung Dong Kim

DISSOLVABLE MICRONEEDLES: APPLICATIONS AND OPPORTUNITIES

Jung Dong Kim and Do Hyeon Jeong discuss dissolvable microneedle technology and its myriad uses.

SILICA NANO-SOLUTIONS FOR SKIN DELIVERY

Dr Aparajita Khatri

Ceramisphere Health

SILICA NANO-SOLUTIONS FOR SKIN DELIVERY

Aparajita Khatri and Christophe A Barbé outline the growth of the dermal delivery market, as well as the challenges it faces. The authors go on to detail a nanocomposite lidocaine patch.

AN INTRADERMAL PLATFORM BUILT FOR INDUSTRY AND PATIENTS

AN INTRADERMAL PLATFORM BUILT FOR INDUSTRY AND PATIENTS

Moe Wehbe, Iman Mansoor and Sahan Ranamukha discuss the potential of intradermal injection for modern medicines and its advantages over the subcutaneous route.

SIMPLIFIED DRUG AND VACCINE DELIVERY USING MICRON’S MICRONEEDLE PATCH

Dr Mark Prausnitz

Micron Biomedical

SIMPLIFIED DRUG AND VACCINE DELIVERY USING MICRON’S MICRONEEDLE PATCH

Devin V McAllister, Sebastien Henry and Mark Prausnitz introduce the company’s dissolving microneedle patch technology, which has global potential, including in the developing world, across a range of vaccine and therapeutic applications.

COST-EFFECTIVE APPROACHES FOR SUCCESSFUL GENERIC DERMAL DRUG PRODUCT AUTHORISATIONS

Prof Marc Brown

COST-EFFECTIVE APPROACHES FOR SUCCESSFUL GENERIC DERMAL DRUG PRODUCT AUTHORISATIONS

Marc Brown, Jon Lenn and Jeremy Dummond discuss various methods and advantages of in vitro bioequivalence studies for topical skin application, and how MedPharm’s unique technologies and experience can be invaluable in the effective development of generics in this field.

QUALITY BY DESIGN IN TDS DEVELOPMENT: BENEFIT OR BUREAUCRATIC BURDEN?

QUALITY BY DESIGN IN TDS DEVELOPMENT: BENEFIT OR BUREAUCRATIC BURDEN?

Petra Botzem and Thomas Hille discuss the Quality-by-Design approach to the development of transdermal drug delivery systems as laid out in ICH guideline Q8.

TERIPARATIDE MICRO-PATCH™: A SOLID MICRONEEDLE PRODUCT NEARING CLINICAL TRIALS

Dr Faz Chowhury

TERIPARATIDE MICRO-PATCH™: A SOLID MICRONEEDLE PRODUCT NEARING CLINICAL TRIALS

Faz Chowdhury details a Micro-Patch™ solid formulation of the parathyroid hormone analogue, teriparatide, for the treatment of osteoporosis.

VACCINE DELIVERY USING THE NEMAURA SOLID DOSE INJECTOR

VACCINE DELIVERY USING THE NEMAURA SOLID DOSE INJECTOR

Joanne Broadhead and Karmen Cheung report an investigation into the delivery of two vaccines using Nemaura Pharma’s solid-dose injection technology.

THE RAPID EVOLUTION OF THE TRANSDERMAL DRUG DELIVERY INDUSTRY SPAWNS INNOVATION

THE RAPID EVOLUTION OF THE TRANSDERMAL DRUG DELIVERY INDUSTRY SPAWNS INNOVATION

Luis Tissone outlines technological developments behind microneedle design including the use of advanced liquid silicone rubber (LSR) and two-component injection technology, and explores the advantages this route offers over traditional intramuscular routes.

1
2
3
Next

Top